|Bid||7.50 x 900|
|Ask||16.20 x 2200|
|Day's range||14.11 - 14.60|
|52-week range||11.47 - 17.99|
|PE ratio (TTM)||10.96|
|Earnings date||24 Jul 2018 - 30 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.33|
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease .
Innoviva, Inc. (INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC and Steel Valley Advisors LLC, a Registered Investment Adviser.
NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ILG ...
On a per-share basis, the Brisbane, California-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 35 cents per share. The biopharmaceutical ...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.
GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base. The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .
Follows Termination of CEO Mike Aguiar GREENWICH, Conn. , Feb. 13, 2018 /PRNewswire/ -- Sarissa Capital Management LP announced today that Sarissa Capital has entered into an agreement with Innoviva, Inc. ...
The Brisbane, California-based company said it had profit of 45 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
Innoviva, Inc. today reported financial results for the fourth quarter and full year 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® from Glaxo Group Limited during the fourth quarter of 2017 were $70.5 million, up 51% from $46.8 million in the fourth quarter of 2016.
Innoviva, Inc. announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m.
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ...
Innoviva, Inc. today announced it implemented the Delaware Court of Chancery’s order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of its affiliates in connection with the Company’s 2017 annual meeting of stockholders, held on April 20, 2017.
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.